{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:46:46Z","timestamp":1791956806656,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01440-2","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:36:25Z","timestamp":1789482985000},"page":"3135-3150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ceftazidime\u2013Avibactam With or Without Aztreonam Versus Other Active Antimicrobials in the Treatment of Bloodstream Infections by Carbapenem-Resistant Klebsiella pneumoniae"],"prefix":"10.1007","volume":"15","author":[{"given":"Rodrigo C.","family":"da Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Arns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson dos S.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiana","family":"Inocente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda de F.","family":"Balbinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik M.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaysa","family":"Pizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme G. L.","family":"S\u00f3rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata D. F.","family":"Klafke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza M.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia C.","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane T. da S.","family":"Kawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5331-4837","authenticated-orcid":false,"given":"Alexandre P.","family":"Zavascki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"1440_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","volume":"25","author":"H Sati","year":"2024","unstructured":"Sati H, Carrara E, Savoldi A, Hansen P, Garlasco J, Campagnaro E, et al. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis. 2024;25:1033\u201343.","journal-title":"Lancet Infect Dis"},{"key":"1440_CR2","doi-asserted-by":"publisher","first-page":"dlag099","DOI":"10.1093\/jacamr\/dlag099","volume":"8","author":"N Macesic","year":"2026","unstructured":"Macesic N, Harris PNA, Mo Y, Gomez-Simmonds A. Carbapenemases: epidemiology, detection and management in a changing global landscape. JAC Antimicrob Resist. 2026;8:dlag099.","journal-title":"JAC Antimicrob Resist"},{"key":"1440_CR3","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1016\/S2666-5247(24)00018-1","volume":"5","author":"FP Sellera","year":"2024","unstructured":"Sellera FP, Lincopan N, Fuentes-Castillo D, Stehling EG, Furlan JPR. Rapid evolution of pan-\u03b2-lactam resistance in Enterobacterales co-producing KPC and NDM: insights from global genomic analysis after the COVID-19 pandemic. Lancet Microbe. 2024;5:e412\u20133.","journal-title":"Lancet Microbe"},{"key":"1440_CR4","volume":"43","author":"LC Antochevis","year":"2025","unstructured":"Antochevis LC, Wilhelm CM, Arns B, Sganzerla D, Sudbrack LO, Nogueira TCRL, et al. World Health Organization priority antimicrobial resistance in and healthcare-associated bloodstream infections in Brazil (ASCENSION): a prospective, multicentre, observational study. Lancet Reg Health Am. 2025;43:101004.","journal-title":"Lancet Reg Health Am"},{"key":"1440_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.mcna.2025.01.003","volume":"109","author":"F Perez","year":"2025","unstructured":"Perez F, El Chakhtoura NG, Bonomo RA. Management of severe infections: multidrug-resistant and carbapenem-resistant Gram-negative bacteria. Med Clin North Am. 2025;109:735\u201347.","journal-title":"Med Clin North Am"},{"key":"1440_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","author":"PD Tamma","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae403.","journal-title":"Clin Infect Dis"},{"key":"1440_CR7","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","volume":"10","author":"A Soriano","year":"2021","unstructured":"Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P. ceftazidime\u2013avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther. 2021;10:1989\u20132034.","journal-title":"Infect Dis Ther"},{"key":"1440_CR8","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s15010-024-02277-y","volume":"52","author":"W Hsu","year":"2024","unstructured":"Hsu W, Chuang M-H, Tsai W-W, Lai C-C, Lai H-Y, Tang H-J. Ceftazidime\u2013avibactam combination therapy versus monotherapy for treating carbapenem-resistant Gram-negative infection: a systemic review and meta-analysis. Infection. 2024;52:2029\u201342.","journal-title":"Infection"},{"key":"1440_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s15010-023-02108-6","volume":"52","author":"J Chen","year":"2024","unstructured":"Chen J, Hu Q, Zhou P, Deng S. Ceftazidime\u2013avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Infection. 2024;52:19\u201328.","journal-title":"Infection"},{"key":"1440_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10096-025-05044-5","volume":"44","author":"N Khoshdel","year":"2025","unstructured":"Khoshdel N, Noursalehigarakani M, Seghatoleslami ZS, Hadavand F, Eghbal E, Nasiri MJ, et al. Efficacy of ceftazidime\u2013avibactam in treating Gram-negative infections: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2025;44:767\u201378.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1440_CR11","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s40121-024-01044-8","volume":"13","author":"B Grabein","year":"2024","unstructured":"Grabein B, Arhin FF, Daikos GL, Moore LSP, Balaji V, Baillon-Plot N. Navigating the current treatment landscape of metallo-\u03b2-lactamase-producing Gram-negative infections: what are the limitations? Infect Dis Ther. 2024;13:2423\u201347.","journal-title":"Infect Dis Ther"},{"key":"1440_CR12","first-page":"101175","volume":"49","author":"IA Huespe","year":"2025","unstructured":"Huespe IA, Huaier Arriazu EF, Sanchez M, Stanek V, Poll\u00e1n JA, Bauque S, et al. Mortality of metallo-\u03b2-lactamase-producing Enterobacterales bacteremias with combined ceftazidime\u2013avibactam plus aztreonam vs other active antibiotics: a multicenter target trial emulation. Lancet Reg Health Am. 2025;49:101175.","journal-title":"Lancet Reg Health Am"},{"key":"1440_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s15010-023-02094-9","volume":"52","author":"RA Sree","year":"2024","unstructured":"Sree RA, Gupta A, Gupta N, Veturi S, Reddy LSK, Begum M, et al. ceftazidime\u2013avibactam alone or in combination with aztreonam versus polymyxins in the management of carbapenem-resistant Klebsiella pneumoniae nosocomial infections (CAPRI study): a retrospective cohort study from South India. Infection. 2024;52:429\u201337.","journal-title":"Infection"},{"key":"1440_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2025.104589","volume":"29","author":"AP Zavascki","year":"2025","unstructured":"Zavascki AP, Chebabo A, Cunha CA, Silva AR, Cuba GT, Santos DWCL, et al. Guideline for antimicrobial treatment of multidrug-resistant Gram-negative infections: practice recommendations of the Brazilian Society of Infectious Diseases. Braz J Infect Dis. 2025;29:104589.","journal-title":"Braz J Infect Dis"},{"key":"1440_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jgar.2024.02.001","volume":"36","author":"B Arns","year":"2024","unstructured":"Arns B, Sorio GGL, Vieceli T, Pereira D, Celestino de Souza \u00c2, Lamb Wink P, et al. Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime\u2013avibactam: a prospective multicentric cohort study. J Glob Antimicrob Resist. 2024;36:393\u20138.","journal-title":"J Glob Antimicrob Resist"},{"key":"1440_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jgar.2024.06.007","volume":"38","author":"CM Wilhelm","year":"2024","unstructured":"Wilhelm CM, Antochevis LC, Magagnin CM, Arns B, Vieceli T, Pereira DC, et al. Susceptibility evaluation of novel beta-lactam\/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil. J Glob Antimicrob Resist. 2024;38:247\u201351.","journal-title":"J Glob Antimicrob Resist"},{"key":"1440_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1473-3099(18)30792-8","volume":"19","author":"AJ Stewardson","year":"2019","unstructured":"Stewardson AJ, Marimuthu K, Sengupta S, Allignol A, El-Bouseary M, Carvalho MJ, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis. 2019;19:601\u201310.","journal-title":"Lancet Infect Dis"},{"key":"1440_CR18","doi-asserted-by":"publisher","first-page":"ofad649","DOI":"10.1093\/ofid\/ofad649","volume":"11","author":"XC Lin","year":"2024","unstructured":"Lin XC, Li CL, Zhang SY, Yang XF, Jiang M. The global and regional prevalence of hospital-acquired carbapenem-resistant infection: a systematic review and meta-analysis. Open Forum Infect Dis. 2024;11:ofad649.","journal-title":"Open Forum Infect Dis"},{"key":"1440_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1473-3099(21)00399-6","volume":"22","author":"M Wang","year":"2022","unstructured":"Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis. 2022;22:401\u201312.","journal-title":"Lancet Infect Dis"},{"key":"1440_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jgar.2024.03.020","volume":"37","author":"MG Wise","year":"2024","unstructured":"Wise MG, Karlowsky JA, Mohamed N, Hermsen ED, Kamat S, Townsend A, et al. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018\u20132022. J Glob Antimicrob Resist. 2024;37:168\u201375.","journal-title":"J Glob Antimicrob Resist"},{"key":"1440_CR21","volume":"40","author":"K Allel","year":"2024","unstructured":"Allel K, Peters A, Haghparast-Bidgoli H, Spencer-Sandino M, Conejeros J, Garcia P, et al. Excess burden of antibiotic-resistant bloodstream infections: evidence from a multicentre retrospective cohort study in Chile, 2018\u20132022. Lancet Reg Health Am. 2024;40:100943.","journal-title":"Lancet Reg Health Am"},{"key":"1440_CR22","unstructured":"EUCAST - Home [Internet]. 2026 [cited 2026 Jul 9]. Available from: https:\/\/www.eucast.org\/."},{"key":"1440_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1469-0691.2010.03294.x","volume":"17","author":"CG Giske","year":"2011","unstructured":"Giske CG, Gezelius L, Samuelsen \u00d8, Warner M, Sundsfjord A, Woodford N. A sensitive and specific phenotypic assay for detection of metallo-\u03b2-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clin Microbiol Infect. 2011;17:552\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"1440_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/jac\/dkx521","volume":"73","author":"H Boutal","year":"2018","unstructured":"Boutal H, Vogel A, Bernabeu S, Devilliers K, Creton E, Cotellon G, et al. A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP- and VIM-type and OXA-48-like carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73:909\u201315.","journal-title":"J Antimicrob Chemother"},{"key":"1440_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01255-23","volume":"62","author":"L Maccari","year":"2024","unstructured":"Maccari L, Ceriana P, Granchetti HN, Pezzaniti AV, Lucero C, Rapoport M, et al. Improved Blue Carba test and Carba NP test for detection and classification of major Class A and B carbapenemases, including dual producers, among Gram-negative bacilli. J Clin Microbiol. 2024;62:e0125523.","journal-title":"J Clin Microbiol"},{"key":"1440_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ndt\/gfae209","volume":"40","author":"F Iatridi","year":"2025","unstructured":"Iatridi F, Carrero JJ, Cornec-Le Gall E, Kanbay M, Luyckx V, Shroff R, et al. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease in children and adults: a commentary from the European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2025;40:273\u201382.","journal-title":"Nephrol Dial Transplant"},{"key":"1440_CR27","unstructured":"HAI Checklists [Internet]. 2026 [cited 2026 Jul 9]. Available from: https:\/\/www.cdc.gov\/nhsn\/hai-checklists."},{"key":"1440_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)\u2020. Pharmacotherapy. 2019;39:10\u201339.","journal-title":"Pharmacotherapy"},{"key":"1440_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","volume":"68","author":"M Tumbarello","year":"2019","unstructured":"Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, et al. Efficacy of ceftazidime\u2013avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68:355\u201364.","journal-title":"Clin Infect Dis"},{"key":"1440_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.780940","volume":"12","author":"J Fang","year":"2021","unstructured":"Fang J, Li H, Zhang M, Shi G, Liu M, Wang Y, et al. Efficacy of ceftazidime\u2013avibactam versus polymyxin B and risk factors affecting clinical outcomes in patients with carbapenem-resistant infections a retrospective study. Front Pharmacol. 2021;12:780940.","journal-title":"Front Pharmacol"},{"key":"1440_CR31","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s40121-022-00682-0","volume":"11","author":"G Zheng","year":"2022","unstructured":"Zheng G, Cai J, Zhang L, Chen D, Wang L, Qiu Y, et al. Ceftazidime\/avibactam-based versus polymyxin B-based therapeutic regimens for the treatment of carbapenem-resistant Klebsiella pneumoniae infection in critically Ill patients: a retrospective cohort study. Infect Dis Ther. 2022;11:1917\u201334.","journal-title":"Infect Dis Ther"},{"key":"1440_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s15010-024-02324-8","volume":"53","author":"H-H Zhuang","year":"2025","unstructured":"Zhuang H-H, Qu Q, Long W-M, Hu Q, Wu X-L, Chen Y, et al. Ceftazidime\/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study. Infection. 2025;53:95\u2013106.","journal-title":"Infection"},{"key":"1440_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. ceftazidime\u2013avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00883-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1440_CR34","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, et al. Efficacy of ceftazidime\u2013avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing Enterobacterales. Clin Infect Dis. 2021;72:1871\u20138.","journal-title":"Clin Infect Dis"},{"key":"1440_CR35","unstructured":"Rossolini GM, Hu F, Sethuraman N, Kamat S, Mohamed N, Stone G, et al. Activity of aztreonam\u2013avibactam and comparators against isolated from bloodstream infections: ATLAS\/ surveillance, 2021\u20132022. Microbiol Spectr. 2026;e0024126."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01440-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01440-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01440-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:02:50Z","timestamp":1791954170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01440-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1440"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01440-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alexandre P. Zavascki is an Editorial Board member of\n                      Infectious Diseases and Therapy.\n                      Alexandre P. Zavascki was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Alexandre P. Zavascki is a research fellow of the National Council for Scientific and Technological Development (CNPq), Ministry of Science and Technology, Brazil. All other authors (Rodrigo C. da Fonseca, Beatriz Arns, Adriana Schmidt, Emerson dos S. Hoffmann, Nadiana Inocente, Amanda de F. Balbinot, Erik M. Martins, Jaysa Pizzi, Guilherme G. L. S\u00f3rio, Renata D. F. Klafke, Luiza M. Perez, Let\u00edcia C. Marinho, Cristiane T. da S. Kawski) declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been conducted in accordance with the Brazilian and international regulations set forth in the following documents: Declaration of Helsinki; Brazilian National Health Council Resolution CNS 466\/2012 and related Brazilian Ministry of Health publications; and 1996 ICH Harmonized Tripartite Guideline for Good Clinical Practice. The study protocol was approved by the research ethics committee (IRB) of Hospital Moinhos de Vento (CAAE 78523124.0.0000.5330).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}